| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effects of oral administration of type II collagen on rheumatoid arthritis.
|
Science
|
1993
|
3.32
|
|
2
|
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
|
Arthritis Rheum
|
1999
|
1.58
|
|
3
|
Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor alpha receptor gene.
|
Arthritis Rheum
|
1997
|
0.97
|
|
4
|
Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.
|
Arthritis Rheum
|
1995
|
0.88
|
|
5
|
Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
|
Aliment Pharmacol Ther
|
2002
|
0.85
|
|
6
|
Health status response of rheumatoid arthritis to treatment with DAB486IL-2.
|
Arthritis Care Res
|
1996
|
0.83
|
|
7
|
Chronic gonococcal arthritis.
|
J Rheumatol
|
1989
|
0.81
|
|
8
|
Idiotypic analyses of anti-DNA antibodies in systemic lupus and monoclonal gammopathy.
|
Ann Inst Pasteur Immunol
|
1989
|
0.79
|
|
9
|
Multisystem disease in post-streptococcal arthritis.
|
Ann Rheum Dis
|
1991
|
0.76
|
|
10
|
Clinical trial: endoscopic evaluation of naproxen etemesil, a naproxen prodrug, vs. naproxen - a proof-of-concept, randomized, double-blind, active-comparator study.
|
Aliment Pharmacol Ther
|
2010
|
0.75
|
|
11
|
Treatment of elderly-onset rheumatoid arthritis.
|
J Am Geriatr Soc
|
1991
|
0.75
|
|
12
|
Iatrogenic osteoporosis.
|
Arch Dermatol
|
1995
|
0.75
|
|
13
|
Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
|
Clin Exp Immunol
|
2005
|
0.75
|
|
14
|
Systemic lupus erythematosus as a cause of failure to thrive in older people.
|
J Am Geriatr Soc
|
1996
|
0.75
|